INmune Bio Inc.
INMB
$1.23
$0.010.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 257.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 257.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 257.14% |
| SG&A Expenses | -6.26% | 46.24% | 18.64% | -19.88% | -0.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.62% | -42.18% | -39.50% | -18.33% | -9.75% |
| Operating Income | 41.32% | 42.18% | 39.50% | 18.33% | 10.09% |
| Income Before Tax | 44.48% | 42.89% | 46.48% | -150.95% | 11.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.48% | 42.89% | 46.48% | -150.95% | 11.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.48% | 42.89% | 46.48% | -150.95% | 11.66% |
| EBIT | 41.32% | 42.18% | 39.50% | 18.33% | 10.09% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 53.01% | 52.24% | 59.37% | -107.96% | 29.22% |
| Normalized Basic EPS | 53.03% | 52.24% | 55.58% | 32.46% | 29.22% |
| EPS Diluted | 53.01% | 52.24% | 59.37% | -107.96% | 29.22% |
| Normalized Diluted EPS | 53.03% | 52.24% | 55.58% | 32.46% | 29.22% |
| Average Basic Shares Outstanding | 18.18% | 19.59% | 31.70% | 20.67% | 24.80% |
| Average Diluted Shares Outstanding | 18.18% | 19.59% | 31.70% | 20.67% | 24.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |